October 13, 2022 October 13, 2022Categories Trial ResultsTrial Results: ECOG-ACRIN Completes the First Randomized Phase 3 Clinical Trial of Neoadjuvant Immunotherapy in Patients with Kidney CancerThe phase III PROSPER RCC clinical trial demonstrated that priming the immune system with nivolumab before surgery, then continuing nivolumab, did not improve recurrence-free survival in patients with high-risk renal cell carcinoma